Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1956 1
1965 1
1967 1
1975 11
1976 9
1977 5
1978 9
1979 14
1980 15
1981 26
1982 15
1983 20
1984 22
1985 18
1986 23
1987 19
1988 18
1989 24
1990 17
1991 26
1992 21
1993 20
1994 28
1995 25
1996 27
1997 25
1998 33
1999 26
2000 24
2001 24
2002 33
2003 33
2004 41
2005 39
2006 42
2007 43
2008 54
2009 54
2010 46
2011 62
2012 76
2013 83
2014 83
2015 97
2016 89
2017 68
2018 94
2019 152
2020 221
2021 180
2022 196
2023 200
2024 73

Text availability

Article attribute

Article type

Publication date

Search Results

2,322 results

Results by year

Filters applied: . Clear all
Page 1
Acetaminophen.
[No authors listed] [No authors listed] 2024 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000253 Free Books & Documents. Review.
Hydroquinone.
[No authors listed] [No authors listed] 2019 Feb 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2019 Feb 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999728 Free Books & Documents. Review.
Cisapride.
[No authors listed] [No authors listed] 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000571 Free Books & Documents. Review.
Different Foot Positioning During Calf Training to Induce Portion-Specific Gastrocnemius Muscle Hypertrophy.
Nunes JP, Costa BDV, Kassiano W, Kunevaliki G, Castro-E-Souza P, Rodacki ALF, Fortes LS, Cyrino ES. Nunes JP, et al. J Strength Cond Res. 2020 Aug;34(8):2347-2351. doi: 10.1519/JSC.0000000000003674. J Strength Cond Res. 2020. PMID: 32735428 Clinical Trial.
Nunes, JP, Costa, BDV, Kassiano, W, Kunevaliki, G, Castro-e-Souza, P, Rodacki, ALF, Fortes, LS, and Cyrino, ES. Different foot positioning during calf training to induce portion-specific gastrocnemius muscle hypertrophy. ...After the training period, there were obse …
Nunes, JP, Costa, BDV, Kassiano, W, Kunevaliki, G, Castro-e-Souza, P, Rodacki, ALF, Fortes, LS, and Cyrino, ES. Different foot …
Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, Søndergaard AL, Tankova TI, Tentolouris N, Buse JB. Frías JP, et al. Lancet Diabetes Endocrinol. 2021 Sep;9(9):563-574. doi: 10.1016/S2213-8587(21)00174-1. Epub 2021 Jul 21. Lancet Diabetes Endocrinol. 2021. PMID: 34293304 Clinical Trial.
Mean change in HbA(1c) from baseline at week 40 was -2.2 percentage points with semaglutide 2.0 mg and -1.9 percentage points with semaglutide 1.0 mg (estimated treatment difference [ETD] -0.23 percentage points [95% CI -0.36 to -0.11]; p=0.0003; trial product estimand) an …
Mean change in HbA(1c) from baseline at week 40 was -2.2 percentage points with semaglutide 2.0 mg and -1.9 percentage points with semagluti …
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F. Mina R, et al. Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14. Lancet Oncol. 2023. PMID: 36528035 Clinical Trial.
Compared with patients with zero HRCA, the risk of death was significantly higher in patients with one HRCA (HR 2.55 [95% CI 1.22-5.36]; p=0.013) and two or more HRCA (HR 6.53 [95% CI 3.24-13.18]; p<0.0001). ...The risk of progression or death was higher in patie …
Compared with patients with zero HRCA, the risk of death was significantly higher in patients with one HRCA (HR 2.55 [95% CI 1.22-5.36]; …
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D'Agostino M, Belotti A, Galli M, Racca M, Zambello R, Gamberi B, Albano D, Bertamini L, Versari A, Grasso M, Sgherza N, Priola C, Fioritoni F, Patriarca F, De Cicco G, Villanova T, Pascarella A, Zucchetta P, Tacchetti P, Fanti S, Mancuso K, Barbato S, Boccadoro M, Musto P, Cavo M, Nanni C. Zamagni E, et al. EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37396807 Free PMC article.
At PM, CMR was achieved in 63% of patients, which was a strong predictor for prolonged PFS in univariate analysis at landmark time PM (HR 0.40, P = 0.0065) and in Cox multivariate analysis (HR 0.31, P = 0.0023). Regarding OS, a trend in favour of CMR was present in …
At PM, CMR was achieved in 63% of patients, which was a strong predictor for prolonged PFS in univariate analysis at landmark time PM (HR 0. …
Airway Analysis in Apert Syndrome.
Forte AJ, Lu X, Hashim PW, Steinbacher DM, Alperovich M, Persing JA, Alonso N. Forte AJ, et al. Plast Reconstr Surg. 2019 Sep;144(3):704-709. doi: 10.1097/PRS.0000000000005937. Plast Reconstr Surg. 2019. PMID: 31461034

RESULTS: Although all of the nasal measurements were consistent with those of the controls, the nasion-to-posterior nasal spine, sphenethmoid-to-posterior nasal spine, sella-to-posterior nasal spine, and basion-to-posterior nasal spine distances were decreased 20 (p < 0

…
RESULTS: Although all of the nasal measurements were consistent with those of the controls, the nasion-to-posterior nasal spine, sphenethmoi …
[Lipothymia].
Fortes LB. Fortes LB. Rev Fac Odontol P Alegre. 1965;7:21-30. Rev Fac Odontol P Alegre. 1965. PMID: 5228476 Portuguese. No abstract available.
Short-Term Fluoride Release from Ion- Releasing Dental Materials.
Banic Vidal LS, Veček NN, Šalinović I, Miletić I, Klarić E, Jukić Krmek S. Banic Vidal LS, et al. Acta Stomatol Croat. 2023 Sep;57(3):229-237. doi: 10.15644/asc57/3/3. Acta Stomatol Croat. 2023. PMID: 37808411 Free PMC article.
After 24 hours, EQUIA Forte HT (p<0.001) and Luminos UN (p<0.05) exhibited significantly higher releases, compared to other tested materials. EQUIA Forte HT maintained the highest release at 48 hours (p<0.001), followed by Cention Fo …
After 24 hours, EQUIA Forte HT (p<0.001) and Luminos UN (p<0.05) exhibited significantly higher releases, compare …
2,322 results